Takeda Pharmaceutical Company Limited (TAK) Competitors & Peers
The 5 companies closest to Takeda Pharmaceutical Company Limited on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| JHPCY | Peer | $13.60 | P/E 37.8RSI 7Cap 45.1 B |
| GDERF | Peer | $228.55 | P/E 62.4RSI 56Cap 53.3 B |
| GALDY | Peer | $43.24 | P/E 59.2RSI 50Cap 50.4 B |
| TKPHF | Peer | $35.89 | RSI 66Cap 57.3 B |
| TEVJF | Peer | $28.40 | P/E 47.3RSI 19Cap 33.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- ARWRPartner
Arrowhead partners with Takeda on fazirsiran for liver disease.
Model-inferred, unverified — treat as a lead, not evidence - PHVSCompetitor
Pharvaris's oral HAE candidates compete with Takeda's approved injectable HAE therapies.
Model-inferred, unverified — treat as a lead, not evidence - SUPNCompetitor
Supernus's Qelbree competes with Takeda's dominant stimulant ADHD drug Vyvanse.
Model-inferred, unverified — treat as a lead, not evidence